Today many cancer patients die as a result of tumors that are non-responsive to commonly used standard platinum chemotherapy drugs. To make matters worse, there is still no accurate way to identify these patients. Our novel method addresses this unmet need in cancer chemotherapy*. Our test will reduce mortality by identifying chemo-resistant patients prior to any drugs being administered, saving them from the unnecessary suffering from ineffective toxic drugs, and giving them a chance at more effective treatments. Our method, tested on ovarian and lung cancers, has the potential to create a paradigm shift in cancer treatment decision making and will ultimately save millions of lives.
AccuDava is also developing an unprecedented glycan-based method to circumvent platinum chemoresistance in cancer patients. Our novel technology increases the drug entry in cancer cells, promoting tumor eradication.
* Patents: Three patents issued and filed in the USA, Canada, and Europe.
Awards
Two Small Business Innovative Research (SBIR) grants from the National Cancer Institute (NCI) awarded to AccuDava (2017-2020).
NIH-Innovative Corps (I-Corps) grant awarded to AccuDava (2018).